Quantbot Technologies LP Invests $6.34 Million in Smith & Nephew SNATS, Inc. $SNN

Quantbot Technologies LP acquired a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 101,123 shares of the medical equipment provider’s stock, valued at approximately $6,342,000.

A number of other large investors also recently modified their holdings of SNN. Clearstead Trust LLC bought a new stake in Smith & Nephew SNATS during the second quarter valued at about $25,000. Addison Advisors LLC purchased a new stake in shares of Smith & Nephew SNATS during the second quarter worth about $43,000. Allworth Financial LP purchased a new stake in shares of Smith & Nephew SNATS during the second quarter worth about $48,000. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS during the 4th quarter valued at approximately $27,000. Finally, Arax Advisory Partners raised its stake in Smith & Nephew SNATS by 142.6% during the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Performance

Shares of SNN opened at $29.29 on Friday. The company’s fifty day moving average is $30.32 and its 200 day moving average is $31.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. Smith & Nephew SNATS, Inc. has a fifty-two week low of $28.56 and a fifty-two week high of $38.79.

Smith & Nephew SNATS Dividend Announcement

The firm also recently announced a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a $0.312 dividend. The ex-dividend date is Friday, October 2nd. This represents a dividend yield of 205.0%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Zacks Research downgraded Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Morgan Stanley restated an “overweight” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, August 5th. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Finally, Barclays downgraded shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.